---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-038045"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2023-10-24T23:59:59+00:00"
generated_at: "2026-06-09T14:36:07.118301+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# TenX Keane Acquisition signs definitive merger with Citius Oncology; $675M equity value

## Summary
- Deal values Citius Oncology at $675M; Citius Pharma receives 67.5M shares at $10/share.
- Citius Pharma to retain ~90% majority ownership in publicly listed New Citius Oncology post-close.
- Transaction expected to close first half 2024, subject to shareholder and regulatory approvals.
- TenX to domesticate from Cayman Islands to Delaware and rename to Citius Oncology, Inc.
- Sponsor 10XYZ Holdings agrees to support deal and waive redemption rights.

## SEC filing metadata
- accession: 0001493152-23-038045
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2023-10-24T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000149315223038045/0001493152-23-038045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000149315223038045/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-038045
- JSON: https://secwatch.observer/filing/0001493152-23-038045.json
- Plain text: https://secwatch.observer/filing/0001493152-23-038045.txt

## Key facts
- Material Agreements
  CITIUS ONCOLOGY, INC. entered into Agreement and Plan of Merger and Reorganization with TenX Keane Acquisition, TenX Merger Sub, Inc., Citius Pharmaceuticals, Inc. (effective 2023-10-23).
  - Action: entry
  - Agreement: merger
  - Counterparty: TenX Keane Acquisition, TenX Merger Sub, Inc., Citius Pharmaceuticals, Inc.
  - Effective: 2023-10-23
  source text: On October 23, 2023, TenX Keane Acquisition, a Cayman Islands exempted company (“ TenX ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement” ), by and among TenX, TenX Merger Sub, Inc., a Delaware corporation and wholly owned Subsidiary of TenX (“ Merger Sub ”), Citius Pharmaceuticals, Inc., a Nevada corporation (“ Citius Pharma ”), and Citius Oncology, Inc., a Delaware corporation and wholly owned subsidiary of Citius Pharma (“ Citius Oncology ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1851484/000149315223038045/0001493152-23-038045-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.